In an exciting announcement, Ocugen, Inc.(NASDAQ: OCGN), a leading biotechnology company known for its groundbreaking gene and cell therapies, has declared a dividend of newly designated Series C Preferred Stock.This move is set to reward existing shareholders and enhance the company’s capital structure.The dividend distribution is scheduled for May 22, 2024, and will provide each shareholder with one one-thousandth of a share of the new Series C Preferred Stock for every outstanding common share held.
Expanding Opportunities through Series C Preferred Stock
Ocugen’s decision to introduce the Series C Preferred Stock as a dividend comes as the company seeks to further solidify its position in the biotech industry.This newly designated stock will not only add value to existing shareholders but also offer them additional benefits in the long run.
As per the terms of this dividend, the Series C Preferred Stock will provide shareholders voting rights on specific stockholder proposals.This inclusion ensures that shareholders maintain influence over crucial decisions, while also supporting Ocugen’s strategic goals and growth initiatives.However, it’s important to note that the Series C Preferred Stock will not be en
Comments